The evaluation will include 1,000 unique procedures across 20 centers worldwide to capture real-world evidence on biopsy closure – one of the most comprehensive data collections of its kind.

Single Pass Inc., a medical technology innovator focused on improving procedural safety in biopsy care, today announced the launch and first enrollment in B-S.A.F.E. (Biopsy with SinglePass: Assessing Fast & Effective Tract Closure) – a global, post-FDA market evaluation to generate real-world evidence of the SinglePass™ electrocautery biopsy closure device.

Despite the millions of solid organ percutaneous biopsies performed successfully each year, unintended bleeding post-procedure is a real risk requiring additional procedures, longer hospital stays, and increased costs. And in rare instances, the complications can be devastating.

The SinglePass device is designed to cauterize the biopsy tract immediately after tissue extraction, offering a novel approach to reduce bleeding complications, enhance procedural efficiency, and optimize patient observation time.

“Single Pass’s global post-market evaluation - B-S.A.F.E. - reflects our commitment to innovation backed by evidence,” said John Zehren, CEO of Single Pass Inc. “We’re honored to work alongside frontline clinicians to validate real-world safety, usability, and performance, bringing an innovative solution for patients undergoing biopsy procedures.”

B-S.A.F.E. is a multicenter post-market device evaluation that will assess reduction in post-biopsy bleeding and complications, post-biopsy observation time and workflow optimization.

“The SinglePass device represents a transformational advancement in the world of core needle biopsy,” said Dr. Alexander Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital Irvine in Irvine, CA. “With the ability of SinglePass to provide immediate and reliable tract closure, we are already witnessing an inevitable shift in the way we manage bleeding risk and patient recovery. I'm proud to contribute to this evaluation and help drive the future standard of care.”

"I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver!” remarked Dr. Francis Kang, Clinical Chief of Interventional Radiology at Robert Wood Johnson University Hospital in New Brunswick, NJ. “This innovative device efficiently seals biopsy channels, significantly reducing bleeding risks and improving patient safety across all my biopsy procedures."

For more information, visit www.singlepass.co.

About Single Pass Inc.

Single Pass Inc. is a privately held medical device company dedicated to enhancing safety and workflow efficiency in image-guided biopsy procedures. Its flagship device, the SinglePass Electrocautery Biopsy Closure Device, enables clinicians to cauterize the biopsy tract in a single step, potentially improving patient outcomes and reducing procedural complexity. The company is headquartered in Lake Forest, California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250702231947/en/

I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver! This innovative device efficiently seals biopsy channels, reducing bleeding risks and improving patient safety across all my biopsy procedures.